seed
Stage
1
Investors
About
Lento Bio is a biotechnology company developing small-molecule topical eye-drop therapeutics that target and reverse age-related molecular damage in the crystalline lens to restore near vision (presbyopia) and potentially prevent cataracts. Their pipeline includes LB-01 and LB-02 for presbyopia and a cataract-prevention indication, in discovery and IND-enabling stages.
Explore Lento Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.